ORIC Pharmaceuticals Q3 2022 Earnings Report
Key Takeaways
ORIC Pharmaceuticals reported its Q3 2022 financial results, highlighting the FDA clearance of the US IND for ORIC-114 and the upcoming presentation of ORIC-533 preclinical data at the ASH Annual Meeting. The company's cash and investments are expected to fund operations into 2H 2024.
Initial Phase 1b data for ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2-mutated cancers, and ORIC-944 in prostate cancer is expected in 1H 2023.
Clinical development of ORIC-114 was expanded with FDA clearance of US IND.
Preclinical data on ORIC-533 will be presented at the 64th American Society of Hematology (ASH) Annual Meeting.
Cash and investments of $218.0 million are expected to fund the current operating plan into 2H 2024.
ORIC Pharmaceuticals
ORIC Pharmaceuticals
Forward Guidance
ORIC anticipates initial Phase 1b data for ORIC-533, ORIC-114, and ORIC-944 in the first half of 2023.
Positive Outlook
- ORIC-533 (oral CD73 inhibitor): Initial Phase 1b data in 1H 2023
- ORIC-114 (brain penetrant EGFR/HER2 exon 20 inhibitor): Initial Phase 1b data in 1H2023
- ORIC-944 (allosteric PRC2 inhibitor): Initial Phase 1b data in 1H 2023